Our Mission

As world experts in the endolysosomal system, we are pioneering a new class of disease-modifying therapeutics for neurodegenerative diseases.

The chances of developing a neurodegenerative disease increase with age. These diseases affect almost 50 percent of people over age 90. With increases in life expectancy, this problem will eventually have devastating impacts on every family directly. In addition, it will create an enormous, unsustainable financial burden on the healthcare system.

 
 

Leadership

To deliver on the therapeutic potential of our foundational science, we have assembled a team with decades of experience in drug development and neurodegenerative disease. We are open to new partnerships with those interested in joining us in this endeavor.

Leadership

1

Leadership Team

1
2

Scientific Advisory Board

2
3

Collaborators

3

Leadership Team

Joel Klein, J.D. - <p>Chief Executive Officer</p>

Joel Klein, J.D.

Chief Executive Officer

Robert Armstrong, Ph.D. - <p>Chairman, Head of Research &#038; Development</p>

Robert Armstrong, Ph.D.

Chairman, Head of Research & Development

Marco Giorgetti, Ph.D. - <p>Chief Scientific Officer</p>

Marco Giorgetti, Ph.D.

Chief Scientific Officer

Kalpana Merchant, Ph.D. - <p>Head of Translational Medicine</p>

Kalpana Merchant, Ph.D.

Head of Translational Medicine

Scott Small, M.D. - <p>Scientific Co-founder</p>

Scott Small, M.D.

Scientific Co-founder

Gregory A. Petsko, D.Phil. - <p>Scientific Co-founder</p>

Gregory A. Petsko, D.Phil.

Scientific Co-founder

George Montgomery - <p>Chief Financial Officer</p>

George Montgomery

Chief Financial Officer